Skip to main content

Advertisement

SpringerLink
Log in

Lipid metabolism in idiopathic pulmonary fibrosis: From pathogenesis to therapy

  • Review
  • Published:
Journal of Molecular Medicine Aims and scope Submit manuscript

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic irreversible interstitial lung disease characterized by a progressive decline in lung function. The etiology of IPF is unknown, which poses a significant challenge to the treatment of IPF. Recent studies have identified a strong association between lipid metabolism and the development of IPF. Qualitative and quantitative analysis of small molecule metabolites using lipidomics reveals that lipid metabolic reprogramming plays a role in the pathogenesis of IPF. Lipids such as fatty acids, cholesterol, arachidonic acid metabolites, and phospholipids are involved in the onset and progression of IPF by inducing endoplasmic reticulum stress, promoting cell apoptosis, and enhancing the expression of pro-fibrotic biomarkers. Therefore, targeting lipid metabolism can provide a promising therapeutic strategy for pulmonary fibrosis. This review focuses on lipid metabolism in the pathogenesis of pulmonary fibrosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

References

  1. Ma H, Wu X, Li Y, Xia Y (2022) Research progress in the molecular mechanisms, therapeutic targets, and drug development of idiopathic pulmonary fibrosis. Front Pharmacol 13(963):054. https://doi.org/10.3389/fphar.2022.963054

    Article  CAS  Google Scholar 

  2. Maher TM, Bendstrup E, Dron L, Langley J, Smith G, Khalid JM, Patel H, Kreuter M (2021) Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res 22(1):197. https://doi.org/10.1186/s12931-021-01791-z

    Article  PubMed  PubMed Central  Google Scholar 

  3. Lederer DJ, Martinez FJ (2018) Idiopathic pulmonary fibrosis. N Engl J Med 378(19):1811–1823. https://doi.org/10.1056/NEJMra1705751

    Article  CAS  PubMed  Google Scholar 

  4. Zheng Q, Cox IA, Campbell JA, Xia Q, Otahal P, de Graaff B, Corte TJ, Teoh AKY, Walters EH, Palmer AJ (2022) Mortality and survival in idiopathic pulmonary fibrosis: A systematic review and meta-analysis. ERJ Open Res 8(1):00591–02021. https://doi.org/10.1183/23120541.00591-2021

  5. Fahy E, Cotter D, Sud M (1811) Subramaniam S (2011) Lipid classification, structures and tools. Biochim Biophys Acta 11:637–47. https://doi.org/10.1016/j.bbalip.2011.06.009

    Article  CAS  Google Scholar 

  6. Agudelo CW, Samaha G, Garcia-Arcos I (2020) Alveolar lipids in pulmonary disease. a review. Lipids Health Dis 19(1):122. https://doi.org/10.1186/s12944-020-01278-8

  7. Beike L, Wrede C, Hegermann J, Lopez-Rodriguez E, Kloth C, Gauldie J, Kolb M, Maus UA, Ochs M, Knudsen L (2019) Surfactant dysfunction and alveolar collapse are linked with fibrotic septal wall remodeling in the tgf-beta1-induced mouse model of pulmonary fibrosis. Lab Invest 99(6):830–852. https://doi.org/10.1038/s41374-019-0189-x

    Article  PubMed  Google Scholar 

  8. Mai C, Verleden SE, McDonough JE, Willems S, De Wever W, Coolen J, Dubbeldam A, Van Raemdonck DE, Verbeken EK, Verleden GM et al (2017) Thin-section ct features of idiopathic pulmonary fibrosis correlated with micro-ct and histologic analysis. Radiology 283(1):252–263. https://doi.org/10.1148/radiol.2016152362

    Article  PubMed  Google Scholar 

  9. Xu Y, Zhang M, Wang Y, Kadambi P, Dave V, Lu LJ, Whitsett JA (2010) A systems approach to mapping transcriptional networks controlling surfactant homeostasis. BMC Genomics 11:451. https://doi.org/10.1186/1471-2164-11-451

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Bujak R, Struck-Lewicka W, Markuszewski MJ, Kaliszan R (2015) Metabolomics for laboratory diagnostics. J Pharm Biomed Anal 113:108–20. https://doi.org/10.1016/j.jpba.2014.12.017

    Article  CAS  PubMed  Google Scholar 

  11. Yan F, Wen Z, Wang R, Luo W, Du Y, Wang W, Chen X (2017) Identification of the lipid biomarkers from plasma in idiopathic pulmonary fibrosis by lipidomics. BMC Pulm Med 17(1):174. https://doi.org/10.1186/s12890-017-0513-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Fahy E, Subramaniam S, Brown HA, Glass CK, Merrill JAH, Murphy RC, Raetz CR, Russell DW, Seyama Y, Shaw W et al (2005) A comprehensive classification system for lipids. J Lipid Res 46(5):839–61. https://doi.org/10.1194/jlr.E400004-JLR200

    Article  CAS  PubMed  Google Scholar 

  13. Agostoni C, Bruzzese MG (1992) fatty acids: their biochemical and functional classification. La Pediatria Medica E Chirurgica : Medical and Surgical Pediatrics 14(5):473–479

    CAS  PubMed  Google Scholar 

  14. Bach D, Wachtel E (2003) Phospholipid/cholesterol model membranes: formation of cholesterol crystallites. Biochim Biophys Acta 1610(2):187–97. https://doi.org/10.1016/s0005-2736(03)00017-8

    Article  CAS  PubMed  Google Scholar 

  15. Gault CR, Obeid LM, Hannun YA (2010) An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol 688

  16. Eibl H (1980) Synthesis of glycerophospholipids. Chem Phys Lipids 26(4):405–429

    Article  CAS  PubMed  Google Scholar 

  17. Flowers MT, Ntambi JM (2008) Role of stearoyl-coenzyme a desaturase in regulating lipid metabolism. Curr Opin Lipidol 19(3):248–256. https://doi.org/10.1097/MOL.0b013e3282f9b54d

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Wakil SJ (1989) Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 28(11):4523–4530

    Article  CAS  PubMed  Google Scholar 

  19. Jung MY, Kang JH, Hernandez DM, Yin X, Andrianifahanana M, Wang Y, Gonzalez-Guerrico A, Limper AH, Lupu R, Leof EB (2018) Fatty acid synthase is required for profibrotic tgf-beta signaling. FASEB J 32(7):3803–3815. https://doi.org/10.1096/fj.201701187R

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Burman A, Tanjore H, Blackwell TS (2018) Endoplasmic reticulum stress in pulmonary fibrosis. Matrix Biol 68–69:355–365. https://doi.org/10.1016/j.matbio.2018.03.015

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Romero F, Hong X, Shah D, Kallen CB, Rosas I, Guo Z, Schriner D, Barta J, Shaghaghi H, Hoek JB et al (2018) Lipid synthesis is required to resolve endoplasmic reticulum stress and limit fibrotic responses in the lung. Am J Respir Cell Mol Biol 59(2):225–236. https://doi.org/10.1165/rcmb.2017-0340OC

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Chu SG, Villalba JA, Liang X, Xiong K, Tsoyi K, Ith B, Ayaub EA, Tatituri RV, Byers DE, Hsu FF et al (2019) Palmitic acid-rich high-fat diet exacerbates experimental pulmonary fibrosis by modulating endoplasmic reticulum stress. Am J Respir Cell Mol Biol 61(6):737–746. https://doi.org/10.1165/rcmb.2018-0324OC

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Kim HS, Yoo HJ, Lee KM, Song HE, Kim SJ, Lee JO, Hwang JJ, Song JW (2021) Stearic acid attenuates profibrotic signalling in idiopathic pulmonary fibrosis. Respirology 26(3):255–263. https://doi.org/10.1111/resp.13949

    Article  PubMed  Google Scholar 

  24. Sunaga H, Matsui H, Ueno M, Maeno T, Iso T, Syamsunarno MR, Anjo S, Matsuzaka T, Shimano H, Yokoyama T et al (2013) Deranged fatty acid composition causes pulmonary fibrosis in elovl6-deficient mice. Nat Commun 4:2563. https://doi.org/10.1038/ncomms3563

    Article  CAS  PubMed  Google Scholar 

  25. Abidi A, Kourda N, Feki M, Ben Khamsa S (2020) Protective effect of tunisian flaxseed oil against bleomycin-induced pulmonary fibrosis in rats. Nutr Cancer 72(2):226–238. https://doi.org/10.1080/01635581.2019.1622741

    Article  CAS  PubMed  Google Scholar 

  26. Janssen CI, Kiliaan AJ (2014) Long-chain polyunsaturated fatty acids (lcpufa) from genesis to senescence: the influence of lcpufa on neural development, aging, and neurodegeneration. Prog Lipid Res 53:1–17. https://doi.org/10.1016/j.plipres.2013.10.002

    Article  CAS  PubMed  Google Scholar 

  27. Yamaguchi A, Botta E, Holinstat M (2022) Eicosanoids in inflammation in the blood and the vessel. Front Pharmacol 13(997):403. https://doi.org/10.3389/fphar.2022.997403

    Article  CAS  Google Scholar 

  28. Charbeneau RP, Peters-Golden M (2005) Eicosanoids: mediators and therapeutic targets in fibrotic lung disease. Clin Sci (Lond) 108(6):479–491

    Article  CAS  PubMed  Google Scholar 

  29. Cheng H, Huang H, Guo Z, Chang Y, Li Z (2021) Role of prostaglandin e2 in tissue repair and regeneration. Theranostics 11(18):8836–8854. https://doi.org/10.7150/thno.63396

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Gabasa M, Royo D, Molina-Molina M, Roca-Ferrer J, Pujols L, Picado C, Xaubet A, Pereda J (2013) Lung myofibroblasts are characterized by down-regulated cyclooxygenase-2 and its main metabolite, prostaglandin e2. PloS One 8(6):e65445. https://doi.org/10.1371/journal.pone.0065445

  31. Dackor RT, Cheng J, Voltz JW, Card JW, Ferguson CD, Garrett RC, Bradbury JA, DeGraff LM, Lih FB, Tomer KB et al (2011) Prostaglandin e2 protects murine lungs from bleomycin-induced pulmonary fibrosis and lung dysfunction. Am J Physiol Lung Cell Mol Physiol 301(5):L645–L655. https://doi.org/10.1152/ajplung.00176.2011

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Zhao J, Shu B, Chen L, Tang J, Zhang L, Xie J, Liu X, Xu Y, Qi S (2016) Prostaglandin e2 inhibits collagen synthesis in dermal fibroblasts and prevents hypertrophic scar formation in vivo. Exp Dermatol 25(8):604–10. https://doi.org/10.1111/exd.13014

    Article  CAS  PubMed  Google Scholar 

  33. Mukherjee S, Sheng W, Michkov A, Sriarm K, Sun R, Dvorkin-Gheva A, Insel PA, Janssen LJ (2019) Prostaglandin e inhibits profibrotic function of human pulmonary fibroblasts by disrupting ca signaling. Am J Physiol Lung Cell Mol Physiol 316(5):L810–L821. https://doi.org/10.1152/ajplung.00403.2018

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Thomas PE, Peters-Golden M, White ES, Thannickal VJ, Moore BB (2007) Pge(2) inhibition of tgf-beta1-induced myofibroblast differentiation is smad-independent but involves cell shape and adhesion-dependent signaling. Am J Physiol Lung Cell Mol Physiol 293(2):L417-28. https://doi.org/10.1152/ajplung.00489.2006

    Article  CAS  PubMed  Google Scholar 

  35. Bärnthaler T, Theiler A, Zabini D, Trautmann S, Stacher-Priehse E, Lanz I, Klepetko W, Sinn K, Flick H, Scheidl S et al (2020) Inhibiting eicosanoid degradation exerts antifibrotic effects in a pulmonary fibrosis mouse model and human tissue. J Allergy Clin Immunol 145(3):818–833. https://doi.org/10.1016/j.jaci.2019.11.032

    Article  CAS  PubMed  Google Scholar 

  36. Zannikou M, Barbayianni I, Fanidis D, Grigorakaki T, Vlachopoulou E, Konstantopoulos D, Fousteri M, Nikitopoulou I, Kotanidou A, Kaffe E et al (2021) Map3k8 regulates cox-2-mediated prostaglandin e2 production in the lung and suppresses pulmonary inflammation and fibrosis. J Immunol 206(3):607–620. https://doi.org/10.4049/jimmunol.2000862

    Article  CAS  PubMed  Google Scholar 

  37. Li JZ, Li ZH, Kang J, Hou XM, Yu RJ (2004) [change of prostaglandin e2 and interleukin-12, interleukin-13 in the bronchoalveolar lavage fluid and the serum of the patients with idiopathic pulmonary fibrosis]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases 27(6):378–380

  38. Basu S (2010) Bioactive eicosanoids: role of prostaglandin f(2alpha) and f(2)-isoprostanes in inflammation and oxidative stress related pathology. Mol Cells 30(5):383–91. https://doi.org/10.1007/s10059-010-0157-1

    Article  CAS  PubMed  Google Scholar 

  39. Oga T, Matsuoka T, Yao C, Nonomura K, Kitaoka S, Sakata D, Kita Y, Tanizawa K, Taguchi Y, Chin K et al (2009) Prostaglandin f(2alpha) receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta. Nat Med 15(12):1426–1430. https://doi.org/10.1038/nm.2066

    Article  CAS  PubMed  Google Scholar 

  40. Beck H, Thaler T, Meibom D, Meininghaus M, Jorissen H, Dietz L, Terjung C, Bairlein M, von Buhler CJ, Anlauf S et al (2020) Potent and selective human prostaglandin f (fp) receptor antagonist (bay-6672) for the treatment of idiopathic pulmonary fibrosis (ipf). J Med Chem 63(20):11639–11662. https://doi.org/10.1021/acs.jmedchem.0c00834

    Article  CAS  PubMed  Google Scholar 

  41. Aihara K, Handa T, Oga T, Watanabe K, Tanizawa K, Ikezoe K, Taguchi Y, Sato H, Chin K, Nagai S, et al (2013) Clinical relevance of plasma prostaglandin f2alpha metabolite concentrations in patients with idiopathic pulmonary fibrosis. PLoS One 8(6):e66,017. https://doi.org/10.1371/journal.pone.0066017

  42. Del Pozo R, Hernandez Gonzalez I, Escribano-Subias P (2017) The prostacyclin pathway in pulmonary arterial hypertension: a clinical review. Expert Rev Respir Med 11(6):491–503. https://doi.org/10.1080/17476348.2017.1317599

    Article  CAS  PubMed  Google Scholar 

  43. Sandig H, Pease JE, Sabroe I (2007) Contrary prostaglandins: the opposing roles of pgd2 and its metabolites in leukocyte function. J Leukoc Biol 81(2):372–382

    Article  CAS  PubMed  Google Scholar 

  44. Cruz-Gervis R, Stecenko AA, Dworski R, Lane KB, Loyd JE, Pierson R, King G, Brigham KL (2002) Altered prostanoid production by fibroblasts cultured from the lungs of human subjects with idiopathic pulmonary fibrosis. Respir Res 3:17

    Article  PubMed  PubMed Central  Google Scholar 

  45. Murakami S, Nagaya N, Itoh T, Kataoka M, Iwase T, Horio T, Miyahara Y, Sakai Y, Kangawa K, Kimura H (2006) Prostacyclin agonist with thromboxane synthase inhibitory activity (ono-1301) attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 290(1):L59–L65

    Article  CAS  PubMed  Google Scholar 

  46. Roberts MJ, May LT, Keen AC, Liu B, Lam T, Charlton SJ, Rosethorne EM, Halls ML (2021) Inhibition of the proliferation of human lung fibroblasts by prostacyclin receptor agonists is linked to a sustained camp signal in the nucleus. Front Pharmacol 12(669):227. https://doi.org/10.3389/fphar.2021.669227

    Article  CAS  Google Scholar 

  47. Roberts MJ, Broome RE, Kent TC, Charlton SJ, Rosethorne EM (2018) The inhibition of human lung fibroblast proliferation and differentiation by gs-coupled receptors is not predicted by the magnitude of camp response. Respir Res 19(1):56. https://doi.org/10.1186/s12931-018-0759-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Kolb M, Orfanos SE, Lambers C, Flaherty K, Masters A, Lancaster L, Silverstein A, Nathan SD (2022) The antifibrotic effects of inhaled treprostinil: An emerging option for ild. Adv Ther 39(9):3881–3895. https://doi.org/10.1007/s12325-022-02229-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Nathan SD, Waxman A, Rajagopal S, Case A, Johri S, DuBrock H, De La Zerda DJ, Sahay S, King C, Melendres-Groves L et al (2021) Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the increase study. Lancet Respir Med 9(11):1266–1274. https://doi.org/10.1016/S2213-2600(21)00165-X

    Article  CAS  PubMed  Google Scholar 

  50. Ayabe S, Kida T, Hori M, Ozaki H, Murata T (2013) Prostaglandin d2 inhibits collagen secretion from lung fibroblasts by activating the dp receptor. J Pharmacol Sci 121(4):312–317

    Article  CAS  PubMed  Google Scholar 

  51. Wiley CD, Brumwell AN, Davis SS, Jackson JR, Valdovinos A, Calhoun C, Alimirah F, Castellanos CA, Ruan R, Wei Y, et al (2019) Secretion of leukotrienes by senescent lung fibroblasts promotes pulmonary fibrosis. JCI Insight 4(24):e130056. https://doi.org/10.1172/jci.insight.130056

  52. Failla M, Genovese T, Mazzon E, Gili E, Muià C, Sortino M, Crimi N, Caputi AP, Cuzzocrea S, Vancheri C, (2006) Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury. Respir Res 7:137

  53. Lu W, Yao X, Ouyang P, Dong N, Wu D, Jiang X, Wu Z, Zhang C, Xu Z, Tang Y et al (2017) Drug repurposing of histone deacetylase inhibitors that alleviate neutrophilic inflammation in acute lung injury and idiopathic pulmonary fibrosis via inhibiting leukotriene a4 hydrolase and blocking ltb4 biosynthesis. J Med Chem 60(5):1817–1828. https://doi.org/10.1021/acs.jmedchem.6b01507

    Article  CAS  PubMed  Google Scholar 

  54. Li X, Xie M, Lu C, Mao J, Cao Y, Yang Y, Wei Y, Liu X, Cao S, Song Y et al (2020) Design and synthesis of leukotriene a4 hydrolase inhibitors to alleviate idiopathic pulmonary fibrosis and acute lung injury. Eur J Med Chem 203(112):614. https://doi.org/10.1016/j.ejmech.2020.112614

    Article  CAS  Google Scholar 

  55. Izumo T, Kondo M, Nagai A (2009) Effects of a leukotriene b4 receptor antagonist on bleomycin-induced pulmonary fibrosis. Eur Respir J 34(6):1444–1451. https://doi.org/10.1183/09031936.00143708

    Article  CAS  PubMed  Google Scholar 

  56. Wilborn J, Bailie M, Coffey M, Burdick M, Strieter R, Peters-Golden M (1996) Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest 97(8):1827–1836

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Henderson WR, Tang LO, Chu SJ, Tsao SM, Chiang GKS, Jones F, Jonas M, Pae C, Wang H, Chi EY (2002) A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med 165(1):108–116

    Article  PubMed  Google Scholar 

  58. Izumo T, Kondo M, Nagai A (2007) Cysteinyl-leukotriene 1 receptor antagonist attenuates bleomycin-induced pulmonary fibrosis in mice. Life Sci 80(20):1882–6. https://doi.org/10.1016/j.lfs.2007.02.038

    Article  CAS  PubMed  Google Scholar 

  59. Shaker OG, Sourour DA (2011) Effect of leukotriene receptor antagonists on lung fibrosis in rats. J Appl Toxicol 31(7):678–84. https://doi.org/10.1002/jat.1625

    Article  CAS  PubMed  Google Scholar 

  60. Yvan-Charvet L, Bonacina F, Guinamard RR, Norata GD (2019) Immunometabolic function of cholesterol in cardiovascular disease and beyond. Cardiovasc Res 115(9):1393–1407. https://doi.org/10.1093/cvr/cvz127

    Article  CAS  PubMed  Google Scholar 

  61. Fireman E, Spitzer S, Grief J, Kivity S, Topilsky M (1996) Cholesterol crystals in bal fluid from patients with idiopathic pulmonary fibrosis. Respir Med 90(6):361–363

    Article  CAS  PubMed  Google Scholar 

  62. Romero F, Shah D, Duong M, Penn RB, Fessler MB, Madenspacher J, Stafstrom W, Kavuru M, Lu B, Kallen CB et al (2015) A pneumocyte-macrophage paracrine lipid axis drives the lung toward fibrosis. Am J Respir Cell Mol Biol 53(1):74–86. https://doi.org/10.1165/rcmb.2014-0343OC

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Angelidis I, Simon LM, Fernandez IE, Strunz M, Mayr CH, Greiffo FR, Tsitsiridis G, Ansari M, Graf E, Strom TM et al (2019) An atlas of the aging lung mapped by single cell transcriptomics and deep tissue proteomics. Nat Commun 10(1):963. https://doi.org/10.1038/s41467-019-08831-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Lund EG, Kerr TA, Sakai J, Li WP, Russell DW (1998) cdna cloning of mouse and human cholesterol 25-hydroxylases, polytopic membrane proteins that synthesize a potent oxysterol regulator of lipid metabolism. J Biol Chem 273(51):34,316–27. https://doi.org/10.1074/jbc.273.51.34316

  65. Ichikawa T, Sugiura H, Koarai A, Kikuchi T, Hiramatsu M, Kawabata H, Akamatsu K, Hirano T, Nakanishi M, Matsunaga K et al (2013) 25-hydroxycholesterol promotes fibroblast-mediated tissue remodeling through nf-kappab dependent pathway. Exp Cell Res 319(8):1176–86. https://doi.org/10.1016/j.yexcr.2013.02.014

    Article  CAS  PubMed  Google Scholar 

  66. Hachisu Y, Murata K, Takei K, Tsuchiya T, Tsurumaki H, Koga Y, Horie T, Takise A, Hisada T (2019) Possible serological markers to predict mortality in acute exacerbation of idiopathic pulmonary fibrosis. Medicina (Kaunas) 55(5):132. https://doi.org/10.3390/medicina55050132

    Article  PubMed  Google Scholar 

  67. Illingworth DR (1993) Lipoprotein metabolism. Am J Kidney Dis 22(1):90–97

    Article  CAS  PubMed  Google Scholar 

  68. Kovanen PT (1987) Regulation of plasma cholesterol by hepatic low-density lipoprotein receptors. Am Heart J 113(2 Pt 2):464–469

    Article  CAS  PubMed  Google Scholar 

  69. Shi X, Chen Y, Liu Q, Mei X, Liu J, Tang Y, Luo R, Sun D, Ma Y, Wu W et al (2022) Ldlr dysfunction induces ldl accumulation and promotes pulmonary fibrosis. Clin Transl Med 12(1):e711. https://doi.org/10.1002/ctm2.711

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Aihara K, Handa T, Nagai S, Tanizawa K, Ikezoe K, Watanabe K, Chihara Y, Harada Y, Yoshimura C, Oga T et al (2013) Impaired endothelium-dependent vasodilator response in patients with pulmonary fibrosis. Respir Med 107(2):269–75. https://doi.org/10.1016/j.rmed.2012.10.005

    Article  PubMed  Google Scholar 

  71. Lennernäs H, Fager G (1997) Pharmacodynamics and pharmacokinetics of the hmg-coa reductase inhibitors. similarities and differences. Clin Pharmacokinet 32(5):403–425

  72. Barale C, Melchionda E, Morotti A, Russo I (2021) Pcsk9 biology and its role in atherothrombosis. Int J Mol Sci 22(11):5880. https://doi.org/10.3390/ijms22115880

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Kreuter M, Bonella F, Maher TM, Costabel U, Spagnolo P, Weycker D, Kirchgaessler KU, Kolb M (2017) Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. Thorax 72(2):148–153. https://doi.org/10.1136/thoraxjnl-2016-208819

    Article  PubMed  Google Scholar 

  74. Kreuter M, Costabel U, Richeldi L, Cottin V, Wijsenbeek M, Bonella F, Bendstrup E, Maher TM, Wachtlin D, Stowasser S et al (2018) Statin therapy and outcomes in trials of nintedanib in idiopathic pulmonary fibrosis. Respiration 95(5):317–326. https://doi.org/10.1159/000486286

    Article  CAS  PubMed  Google Scholar 

  75. Yildirim M, Kayalar O, Atahan E, Oztay F (2022) Atorvastatin attenuates pulmonary fibrosis in mice and human lung fibroblasts, by the regulation of myofibroblast differentiation and apoptosis. J Biochem Mol Toxicol 36(7):e23074. https://doi.org/10.1002/jbt.23074

  76. Santos DM, Pantano L, Pronzati G, Grasberger P, Probst CK, Black KE, Spinney JJ, Hariri LP, Nichols R, Lin Y et al (2020) Screening for yap inhibitors identifies statins as modulators of fibrosis. Am J Respir Cell Mol Biol 62(4):479–492. https://doi.org/10.1165/rcmb.2019-0296OC

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Barochia AV, Kaler M, Weir N, Gordon EM, Figueroa DM, Yao X, Lemma WoldeHanna M, Sampson M, Remaley AT, Grant G, et al (2021) Serum levels of small hdl particles are negatively correlated with death or lung transplantation in an observational study of idiopathic pulmonary fibrosis. Eur Respir J 58(6):2004053. https://doi.org/10.1183/13993003.04053-2020

  78. Podolanczuk AJ, Raghu G, Tsai MY, Kawut SM, Peterson E, Sonti R, Rabinowitz D, Johnson C, Barr RG, Hinckley Stukovsky K et al (2017) Cholesterol, lipoproteins and subclinical interstitial lung disease: the mesa study. Thorax 72(5):472–474. https://doi.org/10.1136/thoraxjnl-2016-209568

    Article  PubMed  Google Scholar 

  79. Kim TH, Lee YH, Kim KH, Lee SH, Cha JY, Shin EK, Jung S, Jang AS, Park SW, Uh ST et al (2010) Role of lung apolipoprotein a-i in idiopathic pulmonary fibrosis: antiinflammatory and antifibrotic effect on experimental lung injury and fibrosis. Am J Respir Crit Care Med 182(5):633–42. https://doi.org/10.1164/rccm.200905-0659OC

    Article  CAS  PubMed  Google Scholar 

  80. Lee E, Lee EJ, Kim H, Jang A, Koh E, Uh ST, Kim Y, Park SW, Park CS (2013) Overexpression of apolipoprotein a1 in the lung abrogates fibrosis in experimental silicosis. PLoS One 8(2):e55827. https://doi.org/10.1371/journal.pone.0055827

  81. Song X, Shi Y, You J, Wang Z, Xie L, Zhang C, Xiong J (2019) D-4f, an apolipoprotein a-i mimetic, suppresses il-4 induced macrophage alternative activation and pro-fibrotic tgf-beta1 expression. Pharm Biol 57(1):470–476. https://doi.org/10.1080/13880209.2019.1640747

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Yung YC, Stoddard NC, Chun J (2014) Lpa receptor signaling: pharmacology, physiology, and pathophysiology. J Lipid Res 55(7):1192–1214. https://doi.org/10.1194/jlr.R046458

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Tager AM, LaCamera P, Shea BS, Campanella GS, Selman M, Zhao Z, Polosukhin V, Wain J, Karimi-Shah BA, Kim ND et al (2008) The lysophosphatidic acid receptor lpa1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 14(1):45–54

    Article  CAS  PubMed  Google Scholar 

  84. Thannickal VJ, Horowitz JC (2006) Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 3(4):350–6. https://doi.org/10.1513/pats.200601-001TK

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Funke M, Zhao Z, Xu Y, Chun J, Tager AM (2012) The lysophosphatidic acid receptor lpa1 promotes epithelial cell apoptosis after lung injury. Am J Respir Cell Mol Biol 46(3):355–64. https://doi.org/10.1165/rcmb.2010-0155OC

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Nathan S, Zhang H, Andreoli M, Leopold PL, Crystal RG (2021) Creb-dependent lpa-induced signaling initiates a pro-fibrotic feedback loop between small airway basal cells and fibroblasts. Respir Res 22(1):97. https://doi.org/10.1186/s12931-021-01677-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Palmer SM, Snyder L, Todd JL, Soule B, Christian R, Anstrom K, Luo Y, Gagnon R, Rosen G (2018) Randomized, double-blind, placebo-controlled, phase 2 trial of bms-986020, a lysophosphatidic acid receptor antagonist for the treatment of idiopathic pulmonary fibrosis. Chest 154(5):1061–1069. https://doi.org/10.1016/j.chest.2018.08.1058

    Article  PubMed  Google Scholar 

  88. Corte TJ, Lancaster L, Swigris JJ, Maher TM, Goldin JG, Palmer SM, Suda T, Ogura T, Minnich A, Zhan X, et al (2021) Phase 2 trial design of bms-986278, a lysophosphatidic acid receptor 1 (lpa) antagonist, in patients with idiopathic pulmonary fibrosis (ipf) or progressive fibrotic interstitial lung disease (pf-ild). BMJ Open Respir Res 8(1):e001026. https://doi.org/10.1136/bmjresp-2021-001026

  89. Huang LS, Fu P, Patel P, Harijith A, Sun T, Zhao Y, Garcia JGN, Chun J, Natarajan V (2013) Lysophosphatidic acid receptor-2 deficiency confers protection against bleomycin-induced lung injury and fibrosis in mice. Am J Respir Cell Mol Biol 49(6):912–922. https://doi.org/10.1165/rcmb.2013-0070OC

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Cartier A, Hla T (2019) Sphingosine 1-phosphate: Lipid signaling in pathology and therapy. Science 366(6463):eaar5551. https://doi.org/10.1126/science.aar5551

  91. Shea BS, Tager AM (2012) Sphingolipid regulation of tissue fibrosis. Open Rheumatol J 6:123–129. https://doi.org/10.2174/1874312901206010123

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Huang LS, Sudhadevi T, Fu P, Punathil-Kannan PK, Ebenezer DL, Ramchandran R, Putherickal V, Cheresh P, Zhou G, Ha AW et al (2020) Sphingosine kinase 1/s1p signaling contributes to pulmonary fibrosis by activating hippo/yap pathway and mitochondrial reactive oxygen species in lung fibroblasts. Int J Mol Sci 21(6):2064. https://doi.org/10.3390/ijms21062064

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Milara J, Navarro R, Juan G, Peiro T, Serrano A, Ramon M, Morcillo E, Cortijo J (2012) Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary fibrosis and mediates epithelial to mesenchymal transition. Thorax 67(2):147–56. https://doi.org/10.1136/thoraxjnl-2011-200026

    Article  PubMed  Google Scholar 

  94. Huang LS, Berdyshev E, Mathew B, Fu P, Gorshkova IA, He D, Ma W, Noth I, Ma SF, Pendyala S et al (2013) Targeting sphingosine kinase 1 attenuates bleomycin-induced pulmonary fibrosis. FASEB J 27(4):1749–1760. https://doi.org/10.1096/fj.12-219634

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Sobel K, Menyhart K, Killer N, Renault B, Bauer Y, Studer R, Steiner B, Bolli MH, Nayler O, Gatfield J (2013) Sphingosine 1-phosphate (s1p) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via s1p2 and s1p3 receptors and smad-independent signaling. J Biol Chem 288(21):14839–51. https://doi.org/10.1074/jbc.M112.426726

  96. Kono Y, Nishiuma T, Nishimura Y, Kotani Y, Okada T, Nakamura S, Yokoyama M (2007) Sphingosine kinase 1 regulates differentiation of human and mouse lung fibroblasts mediated by tgf-beta1. Am J Respir Cell Mol Biol 37(4):395–404. https://doi.org/10.1165/rcmb.2007-0065OC

    Article  CAS  PubMed  Google Scholar 

  97. Knipe RS, Spinney JJ, Abe EA, Probst CK, Franklin A, Logue A, Giacona F, Drummond M, Griffith J, Brazee PL et al (2022) Endothelial-specific loss of sphingosine-1-phosphate receptor 1 increases vascular permeability and exacerbates bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 66(1):38–52. https://doi.org/10.1165/rcmb.2020-0408OC

    Article  CAS  PubMed  Google Scholar 

  98. Shea BS, Brooks SF, Fontaine BA, Chun J, Luster AD, Tager AM (2010) Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury. Am J Respir Cell Mol Biol 43(6):662–673. https://doi.org/10.1165/rcmb.2009-0345OC

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Oo ML, Thangada S, Wu MT, Liu CH, Macdonald TL, Lynch KR, Lin CY, Hla T (2007) Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem 282(12):9082–9. https://doi.org/10.1074/jbc.M610318200

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work was supported by the National Natural Science Foundation of China (No. 82170076).

Author information

Authors and Affiliations

  1. Department of Pulmonary and Critical Care Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, Jiangsu, China

    Ranxun Chen & Jinghong Dai

Authors
  1. Ranxun Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jinghong Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Jinghong Dai conceived the study. Ranxun Chen drafted the manuscript and drew the figure. All the authors were involved in revising the paper and approved the submitted version.

Corresponding author

Correspondence to Jinghong Dai.

Ethics declarations

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Conflict of interest

The authors declare no competing interests.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, R., Dai, J. Lipid metabolism in idiopathic pulmonary fibrosis: From pathogenesis to therapy. J Mol Med 101, 905–915 (2023). https://doi.org/10.1007/s00109-023-02336-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00109-023-02336-1

Keywords

Search

Navigation